Medigene Expands Patent Portfolio in Japan for iM-TCR Technology Enhancing TCR-T Safety and Efficacy
Tuesday, March 05, 2024
Medigene AG has recently received a patent from the Japan Patent Office for its inducible Medigene T cell receptor (iM-TCR), a mechanism designed to regulate the efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies.
Selwyn Ho, CEO at Medigene, expressed satisfaction with the patent grant, noting its importance in expanding the company's intellectual property portfolio. He emphasized the potential of the iM-TCR to provide tailored efficacy and safety for individual patients by controlling TCR activity post-administration. Ho also highlighted the iM-TCR as an example of Medigene's End-to-End Platform, which includes various proprietary armoring and enhancement technologies. By combining the iM-TCR with their optimal 3S (sensitive, specific, and safe) TCRs, Medigene aims to deliver innovative solutions that optimize the safety and efficacy of TCR-T therapies.
TCR-T therapies have demonstrated effectiveness in killing tumor cells, but excessive T cell activation can lead to issues such as premature exhaustion, cell death, and unwanted inflammatory responses. The iM-TCR technology addresses these concerns by modulating TCR surface expression, enabling precise adjustment of activity against tumor cells while reducing inflammatory responses in the body. This feature is particularly promising for sensitive organs affected by sustained inflammatory reactions caused by T cells, such as those seen in brain or liver cancer.
Source: medigene.com
